Enovis (NYSE:ENOV) Downgraded by Wall Street Zen to “Hold”

Wall Street Zen downgraded shares of Enovis (NYSE:ENOV) from a buy rating to a hold rating in a research note issued to investors on Sunday morning,Wall Street Zen reports.

ENOV has been the subject of a number of other reports. Evercore set a $32.00 price target on shares of Enovis in a report on Monday, July 6th. Zacks Research upgraded Enovis from a “strong sell” rating to a “hold” rating in a research note on Wednesday, July 29th. UBS Group reiterated a “buy” rating and issued a $51.00 price objective (up from $50.00) on shares of Enovis in a research note on Tuesday, July 28th. BTIG Research cut their price objective on Enovis from $40.00 to $36.00 and set a “buy” rating for the company in a research report on Tuesday, September 1st. Finally, Weiss Ratings raised Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 21st. Ten research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $40.38.

Enovis Trading Down 0.1%

NYSE:ENOV opened at $18.03 on Friday. Enovis has a 12 month low of $17.30 and a 12 month high of $34.28. The firm has a market cap of $1.04 billion, a price-to-earnings ratio of -0.94 and a beta of 1.31. The company has a quick ratio of 1.00, a current ratio of 1.98 and a debt-to-equity ratio of 0.84. The company’s 50 day moving average is $24.55 and its 200-day moving average is $23.89.

Enovis (NYSE:ENOV) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.90 earnings per share for the quarter, topping analysts’ consensus estimates of $0.85 by $0.05. Enovis had a negative net margin of 47.96% and a positive return on equity of 12.03%. The business had revenue of $582.78 million during the quarter, compared to analysts’ expectations of $581.84 million. During the same period in the previous year, the company earned $0.79 earnings per share. Enovis’s revenue for the quarter was up 3.2% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Equities analysts anticipate that Enovis will post 3.15 EPS for the current year.

Insider Activity

In related news, CEO Damien Mcdonald acquired 13,035 shares of the company’s stock in a transaction dated Friday, September 4th. The shares were bought at an average price of $19.15 per share, for a total transaction of $249,620.25. Following the acquisition, the chief executive officer owned 247,077 shares in the company, valued at $4,731,524.55. This trade represents a 5.57% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Oliver Engert acquired 5,140 shares of the business’s stock in a transaction dated Thursday, September 3rd. The shares were bought at an average cost of $19.46 per share, with a total value of $100,024.40. Following the transaction, the insider directly owned 61,238 shares of the company’s stock, valued at $1,191,691.48. The trade was a 9.16% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders have bought 23,293 shares of company stock worth $449,599. Insiders own 2.90% of the company’s stock.

Hedge Funds Weigh In On Enovis

Several large investors have recently added to or reduced their stakes in ENOV. Allworth Financial LP grew its stake in shares of Enovis by 59.7% in the 2nd quarter. Allworth Financial LP now owns 1,744 shares of the company’s stock valued at $36,000 after purchasing an additional 652 shares during the period. IFP Advisors Inc boosted its stake in Enovis by 5,590.5% in the 2nd quarter. IFP Advisors Inc now owns 1,195 shares of the company’s stock valued at $25,000 after buying an additional 1,174 shares in the last quarter. Amundi boosted its stake in Enovis by 2.3% in the 1st quarter. Amundi now owns 74,184 shares of the company’s stock valued at $1,688,000 after buying an additional 1,677 shares in the last quarter. Handelsbanken Fonder AB grew its position in Enovis by 9.3% in the second quarter. Handelsbanken Fonder AB now owns 21,117 shares of the company’s stock valued at $437,000 after acquiring an additional 1,800 shares during the period. Finally, Integrated Wealth Concepts LLC bought a new stake in Enovis in the second quarter valued at $39,000. Institutional investors and hedge funds own 98.45% of the company’s stock.

Enovis Company Profile

Enovis Corporation is a medical technology company that develops, manufactures and distributes products designed to improve patient mobility, support recovery and restore physical function. Its offerings serve orthopedic, sports medicine, rehabilitation and pain-management markets, with products used by healthcare professionals, athletes and patients.

The company’s product portfolio includes orthopedic braces and supports, surgical solutions, cold and compression therapy systems, rehabilitation equipment, physical therapy devices and recovery technologies.